OBJECTIVES: To investigate the long-term outcome of patients with acute ST-segment elevation myocardial infarction (STEMI) and a chronic total occlusion (CTO) in a non-infarct-related artery (IRA) and the risk factors for mortality. METHODS: The enrolled cohort comprised 323 patients with STEMI and multivessel diseases (MVD) that received a primary percutaneous coronary intervention between January 2008 and November 2013. The patients were divided into two groups: the CTO group (n = 97) and the non-CTO group (n = 236). The long-term major adverse cardiovascular and cerebrovascular events (MACCE) experienced by each group were compared. RESULTS: The rates of all-cause mortality and MACCE were significantly higher in the CTO group than they were in the non-CTO group. Cox regression analysis showed that an age ≥ 65 years (OR = 3.94, 95% CI: 1.47-10.56, P = 0.01), a CTO in a non-IRA(OR = 5.09, 95% CI: 1.79 ~ 14.54, P < 0.01), an in-hospital Killip class ≥ 3 (OR = 4.32, 95% CI: 1.71 ~ 10.95, P < 0.01), and the presence of renal insufficiency (OR = 5.32, 95% CI: 1.49 ~ 19.01, P = 0.01), stress ulcer with gastraintestinal bleeding (SUB) (OR = 6.36, 95% CI: (1.45 ~ 28.01, P = 0.01) were significantly related the 10-year mortality of patients with STEMI and MVD; an in-hospital Killip class ≥ 3 (OR = 2.97,95% CI:1.46 ~ 6.03, P < 0.01) and the presence of renal insufficiency (OR = 5.61, 95% CI: 1.19 ~ 26.39, P = 0.03) were significantly related to the 10-year mortality of patients with STEMI and a CTO. CONCLUSIONS: The presence of a CTO in a non-IRA, an age ≥ 65 years, an in-hospital Killip class ≥ 3, and the presence of renal insufficiency, and SUB were independent risk predictors for the long-term mortality of patients with STEMI and MVD; an in-hospital Killip class ≥ 3 and renal insufficiency were independent risk predictors for the long-term mortality of patients with STEMI and a CTO.
OBJECTIVES: To investigate the long-term outcome of patients with acute ST-segment elevation myocardial infarction (STEMI) and a chronic total occlusion (CTO) in a non-infarct-related artery (IRA) and the risk factors for mortality. METHODS: The enrolled cohort comprised 323 patients with STEMI and multivessel diseases (MVD) that received a primary percutaneous coronary intervention between January 2008 and November 2013. The patients were divided into two groups: the CTO group (n = 97) and the non-CTO group (n = 236). The long-term major adverse cardiovascular and cerebrovascular events (MACCE) experienced by each group were compared. RESULTS: The rates of all-cause mortality and MACCE were significantly higher in the CTO group than they were in the non-CTO group. Cox regression analysis showed that an age ≥ 65 years (OR = 3.94, 95% CI: 1.47-10.56, P = 0.01), a CTO in a non-IRA(OR = 5.09, 95% CI: 1.79 ~ 14.54, P < 0.01), an in-hospital Killip class ≥ 3 (OR = 4.32, 95% CI: 1.71 ~ 10.95, P < 0.01), and the presence of renal insufficiency (OR = 5.32, 95% CI: 1.49 ~ 19.01, P = 0.01), stress ulcer with gastraintestinal bleeding (SUB) (OR = 6.36, 95% CI: (1.45 ~ 28.01, P = 0.01) were significantly related the 10-year mortality of patients with STEMI and MVD; an in-hospital Killip class ≥ 3 (OR = 2.97,95% CI:1.46 ~ 6.03, P < 0.01) and the presence of renal insufficiency (OR = 5.61, 95% CI: 1.19 ~ 26.39, P = 0.03) were significantly related to the 10-year mortality of patients with STEMI and a CTO. CONCLUSIONS: The presence of a CTO in a non-IRA, an age ≥ 65 years, an in-hospital Killip class ≥ 3, and the presence of renal insufficiency, and SUB were independent risk predictors for the long-term mortality of patients with STEMI and MVD; an in-hospital Killip class ≥ 3 and renal insufficiency were independent risk predictors for the long-term mortality of patients with STEMI and a CTO.
Entities:
Keywords:
Acute ST segment elevation myocardial infarction; Chronic total occlusion; Percutaneous coronary intervention; Prognosis
Authors: L David Hillis; Peter K Smith; Jeffrey L Anderson; John A Bittl; Charles R Bridges; John G Byrne; Joaquin E Cigarroa; Verdi J Disesa; Loren F Hiratzka; Adolph M Hutter; Michael E Jessen; Ellen C Keeley; Stephen J Lahey; Richard A Lange; Martin J London; Michael J Mack; Manesh R Patel; John D Puskas; Joseph F Sabik; Ola Selnes; David M Shahian; Jeffrey C Trost; Michael D Winniford Journal: J Am Coll Cardiol Date: 2011-11-07 Impact factor: 24.094
Authors: R J van der Schaaf; J R Timmer; J P Ottervanger; J C A Hoorntje; M-J de Boer; H Suryapranata; F Zijlstra; J-H E Dambrink Journal: Heart Date: 2006-04-27 Impact factor: 5.994
Authors: Shamir R Mehta; David A Wood; Robert F Storey; Roxana Mehran; Kevin R Bainey; Helen Nguyen; Brandi Meeks; Giuseppe Di Pasquale; Jose López-Sendón; David P Faxon; Laura Mauri; Sunil V Rao; Laurent Feldman; P Gabriel Steg; Álvaro Avezum; Tej Sheth; Natalia Pinilla-Echeverri; Raul Moreno; Gianluca Campo; Benjamin Wrigley; Sasko Kedev; Andrew Sutton; Richard Oliver; Josep Rodés-Cabau; Goran Stanković; Robert Welsh; Shahar Lavi; Warren J Cantor; Jia Wang; Juliet Nakamya; Shrikant I Bangdiwala; John A Cairns Journal: N Engl J Med Date: 2019-09-01 Impact factor: 91.245
Authors: Bimmer E P M Claessen; René J van der Schaaf; Niels J Verouden; Nienke K Stegenga; Annemarie E Engstrom; Krischan D Sjauw; Wouter J Kikkert; Marije M Vis; Jan Baan; Karel T Koch; Robbert J de Winter; Jan G P Tijssen; Jan J Piek; José P S Henriques Journal: JACC Cardiovasc Interv Date: 2009-11 Impact factor: 11.195
Authors: David S Wald; Joan K Morris; Nicholas J Wald; Alexander J Chase; Richard J Edwards; Liam O Hughes; Colin Berry; Keith G Oldroyd Journal: N Engl J Med Date: 2013-09-01 Impact factor: 91.245
Authors: Anthony H Gershlick; Jamal Nasir Khan; Damian J Kelly; John P Greenwood; Thiagarajah Sasikaran; Nick Curzen; Daniel J Blackman; Miles Dalby; Kathryn L Fairbrother; Winston Banya; Duolao Wang; Marcus Flather; Simon L Hetherington; Andrew D Kelion; Suneel Talwar; Mark Gunning; Roger Hall; Howard Swanton; Gerry P McCann Journal: J Am Coll Cardiol Date: 2015-03-17 Impact factor: 24.094